---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-22-000056"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T15:15:53.172632+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated

## Summary
- Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.
- Adjusted EBITDA $132.5M (69% margin), down from $154.9M prior year.
- Nucleic Acid Production revenue $174.9M, down 4% YoY; COVID-19 CleanCap revenue estimated $126.5M.
- Biologics Safety Testing revenue $16.4M, down 1% YoY.
- FY2022 guidance updated for revenue, Adjusted EBITDA, and Adjusted EPS; specific figures not provided in excerpt.

## SEC filing metadata
- accession: 0001823239-22-000056
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/0001823239-22-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/mrvi-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-22-000056
- JSON: https://secwatch.observer/filing/0001823239-22-000056.json
- Plain text: https://secwatch.observer/filing/0001823239-22-000056.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $191.3 million, net income $99.7 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $191.3 million
  - Net income: $99.7 million
  - Result: reported results
  source text: Quarterly revenue of $191.3 million, Net income of $99.7 million, and Adjusted EBITDA margins of 69%;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/0001823239-22-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.